Moreover, it has been demonstrated that TZDs (pioglitazone, rosiglitazone), which are insulin-sensitizing medications used in T2D, decreased NF-κB mRNA in mouse lung tissue [55], mouse primary cholangiocytes [56], and human vascular endothelial cells (HUVEC) [57]. This evidence concerns the gene NFKB1 and type 2 diabetes mellitus.